Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBRUTINIB vs ACALABRUTINIB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Marginal zone lymphoma (MZL) in patients who require systemic therapy and have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy,Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.
100 mg orally every 12 hours.
Terminal half-life is approximately 4-6 hours, supporting twice-daily dosing for sustained BTK inhibition.
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Primarily metabolized by cytochrome P450 3A4 (CYP3A4). Minor metabolism by CYP2D6. The active metabolite is PCI-45227.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C8 and glutathione conjugation.
Primarily fecal (80%) as metabolites, with renal excretion accounting for <10% (mostly as metabolites).
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
97.3% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Apparent Vd is approximately 10,000 L (large), indicating extensive tissue distribution.
Approximately 34 L (approx. 0.5 L/kg for a 70 kg adult), indicating moderate distribution into tissues.
Oral bioavailability is 62% (range 52-74%) under fasted conditions; food increases AUC by 1.7-fold.
Oral bioavailability: approximately 70–75% (absolute bioavailability not determined in humans; estimate based on mass balance and exposure data).
No dose adjustment required for creatinine clearance ≥25 m L/min. Insufficient data for patients with Cr Cl <25 m L/min or on dialysis.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg orally once daily.
Child-Pugh class A: No adjustment. Child-Pugh class B: Reduce dose to 280 mg once daily. Child-Pugh class C: Reduce dose to 140 mg once daily.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 100 mg orally once daily. Child-Pugh C: Avoid use.
Adolescents (≥12 years): 420 mg once daily; weight-based dosing not established. For pediatric patients <12 years: not approved.
Not approved for patients <18 years; safety and efficacy not established.
No specific dose adjustment; monitor for cardiac adverse events (atrial fibrillation, hypertension) and bleeding risk due to higher incidence in elderly.
No specific dose adjustment; monitor for toxicity, especially infections and bleeding.
Hemorrhage: Fatal bleeding events have occurred in patients receiving ibrutinib. Major hemorrhage (e.g., gastrointestinal, intracranial) has been reported. Monitor for signs of bleeding. Consider benefit-risk of holding ibrutinib for 3-7 days pre- and post-surgery depending on procedure.
No boxed warning is included in the FDA-approved prescribing information.
Hemorrhage: Increased risk of bleeding, especially in patients on anticoagulants or antiplatelet agents. Avoid concomitant use of warfarin.,Infections: Fatal and serious infections (including bacterial, viral, fungal) have occurred. Consider prophylaxis in patients at increased risk.,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia have occurred. Monitor blood counts monthly.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor cardiac function, especially in patients with cardiac risk factors.,Hypertension: New-onset or worsening hypertension has been reported. Monitor blood pressure and manage appropriately.,Second primary malignancies: Other malignancies (including skin cancers) have occurred. Perform skin cancer monitoring.,Tumor lysis syndrome: Risk is increased in patients with high tumor burden. Monitor and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have been observed. Monitor hepatic function.
Hemorrhage: Fatal bleeding events have occurred; monitor for bleeding and manage appropriately,Infections: Serious infections (including opportunistic infections) have occurred; consider prophylaxis,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia; monitor blood counts,Second primary malignancies: Including skin cancers; advise sun protection,Atrial fibrillation and flutter: Monitor for cardiac arrhythmias,Hepatotoxicity: Elevations of liver enzymes; monitor hepatic function
Concomitant use with warfarin or other vitamin K antagonists (increased bleeding risk) is not recommended but not absolutely contraindicated; use with caution.,Severe hepatic impairment (Child-Pugh class C) – use not recommended.
None
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they can increase drug levels and toxicity. Take with a full glass of water; may be taken with or without food but avoid high-fat meals as they may increase absorption variability.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition increasing acalabrutinib exposure. No other significant food interactions.
Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotoxic at exposures below the human AUC at the clinical dose. There are no adequate and well-controlled studies in pregnant women. Use during first trimester may cause structural abnormalities; second and third trimester use may impair fetal B-cell development and hematopoiesis.
Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, no adequate data; however, based on mechanism and animal findings, there is potential risk of teratogenicity, especially during first trimester. Use during pregnancy should be avoided unless maternal benefit outweighs fetal risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Ibrutinib and its active metabolite are detected in rat milk at concentrations higher than maternal plasma. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 week after last dose.
No data on acalabrutinib in human milk. Based on molecular weight and pharmacokinetics, excretion into breast milk is likely. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants, advise not to breastfeed during treatment and for 2 weeks after last dose.
No specific dosing adjustments for pregnancy have been established due to lack of human pharmacokinetic data. Pregnancy may alter drug clearance via increased hepatic metabolism and renal function; however, no dose adjustment recommendations can be made. Use only if maternal benefit outweighs fetal risk, with consideration of therapeutic drug monitoring if available.
No established dosing adjustments for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may affect exposure; however, no specific dose recommendations are available. If used, therapeutic drug monitoring is not established; close clinical monitoring for efficacy and toxicity is advised.
Monitor for atrial fibrillation (occurrence ~6-16%, higher risk in elderly). Obtain baseline ECG and monitor for bleeding due to antiplatelet effect (avoid concurrent anticoagulants unless necessary). Check for tumor lysis syndrome risk, especially in high tumor burden. Ibrutinib is a strong CYP3A4 inhibitor; avoid co-administration with sensitive CYP3A4 substrates or adjust doses. Monitor for hypertension and myelosuppression.
Monitor for bleeding, especially if on antiplatelet or anticoagulant therapy. Acalabrutinib is a selective BTK inhibitor with minimal off-target effects compared to ibrutinib, but still carries risks of atrial fibrillation, hypertension, and infections. Start with 100 mg twice daily until progression or unacceptable toxicity. Administer with a full glass of water; do not open capsules. Consider dose reduction for severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed; do not miss doses or stop without consulting your doctor.,Take capsules whole with water at the same time each day; do not open or chew.,Avoid grapefruit, Seville oranges, and starfruit during treatment.,Report any unusual bleeding, bruising, or black/tarry stools immediately.,Contact your healthcare provider if you experience irregular heartbeat, chest pain, or dizziness.,Use effective contraception during treatment and for 1 month after last dose.,Do not take with strong CYP3A4 inhibitors unless directed; avoid St. John's wort.
Take exactly as prescribed, twice daily about 12 hours apart.,Swallow capsules whole with water; do not crush or chew.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any signs of bleeding (unusual bruising, black/tarry stools, blood in urine) or infection (fever, chills) immediately.,Use effective contraception during treatment and for at least 1 week after last dose.,Do not stop or change dose without consulting your doctor.,Wash hands frequently and avoid crowds to reduce infection risk.
"Ibrutinib, a potent Bruton's tyrosine kinase inhibitor, is primarily metabolized by CYP3A4. Saquinavir, a protease inhibitor and potent CYP3A4 inhibitor, may significantly increase the plasma concentration of ibrutinib by reducing its clearance. This elevation in ibrutinib exposure can potentiate its adverse effects, including myelosuppression, atrial fibrillation, hemorrhage, and infections, necessitating dose adjustment or alternative therapy."
"Ibrutinib, a Bruton's tyrosine kinase inhibitor, can inhibit organic anion transporters (OATs), leading to decreased renal clearance of sulfamethoxazole. This results in increased plasma concentrations of sulfamethoxazole, potentially enhancing its therapeutic effects and risk of dose-dependent toxicities such as hypersensitivity reactions, hematologic abnormalities, and crystalluria. Patients may experience prolonged QT interval or decreased renal function due to sulfamethoxazole accumulation."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBRUTINIB vs ACALABRUTINIB, answered by our medical review team.
IBRUTINIB is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in BTK's active site, leading to irreversible inhibition. BTK is essential for B-cell receptor signaling and survival of malignant B cells. Inhibition of BTK blocks pathways that promote B-cell proliferation, migration, and adhesion.. ACALABRUTINIB is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBRUTINIB and ACALABRUTINIB depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBRUTINIB is: Adults: 560 mg orally once daily (4 capsules of 140 mg each) for mantle cell lymphoma; 420 mg once daily (3 capsules of 140 mg) for chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, or chronic graft-versus-host disease.. The standard adult dose of ACALABRUTINIB is: 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBRUTINIB and ACALABRUTINIB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBRUTINIB is classified as Category D/X. Based on animal studies and mechanism of action (BTK inhibition), ibrutinib is expected to cause fetal harm. In animal reproduction studies, ibrutinib was teratogenic and embryotox. ACALABRUTINIB is classified as Category C. Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.